French pharma major Sanofi (Euronext: SAN) has been granted EU approval to market Cablivi (caplacizumab) for episodes of a rare and life-threatening genetic disorder, acquired thrombotic thrombocytopenic purpura (aTTP).
Cablivi, an anti-vWF nanobody, is the first product specifically indicated for the treatment of aTTP, and the company's first nanobody-based medicine to receive approval.
The current standard-of-care treatment, daily plasma exchange (PEX) and immunosuppression, is not enough to improve prevent mortality rates of up to 20%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze